China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its MFG14 facility in Hangzhou has been released for manufacturing microbial-derived products. The facility has been successfully performing Chemistry, Manufacturing, and Controls (CMC) projects for multiple clients since early 2022, demonstrating the company’s capability to provide services from DNA to current Good Manufacturing Practice (cGMP) manufacturing for products derived from microbial fermentation.
Microbial Platform and Services
WuXi Biologics’ microbial platform offers end-to-end CMC services, including strain development, process and analytical development, cGMP manufacturing, and quality control (QC) release. These services are provided at centralized facilities within the company’s Biologics Integrated Innovation Center in Hangzhou. In November 2020, WuXi Biologics launched the Biologics Integrated Innovation Center in Hangzhou, Zhejiang province, to provide comprehensive services for next-generation biological products based on microbial fermentation technologies.-Fineline Info & Tech
